Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

109.08 +0.88 (+0.81%)
Official Closing Price Updated: 7:00 PM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
News headline image
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal ↗
Via MarketBeat
News headline image
Navigating the MedTech Correction: A Deep-Dive into Boston Scientific (NYSE: BSX)
February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left... 
Via Finterra
Topics Product Recall World Trade
News headline image
2 Healthcare Dividend Stocks That are Just What the Doctor Ordered ↗
AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Northfield Bancorp Inc. (Nasdaq - NFBK), Coterra Energy Inc. (NYSE - CTRA), Exact Sciences Corporation (Nasdaq – EXAS), Semrush Holdings, Inc. (NYSE – SEMR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
The Best Dividend King to Buy With $150 ↗
The stock is near its 52-week low. 
Via The Motley Fool
News headline image
Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist ↗
These market giants make great long-term investments. 
Via The Motley Fool
News headline image
5 Insightful Analyst Questions From Abbott Laboratories’s Q4 Earnings Call
Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing challenges in its nutrition segment. Management attributed this... 
Via StockStory
Topics Earnings
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗
Via Chartmill
News headline image
3 Reasons to Buy This Dividend King After Its Steep Sell-Off ↗
Investors' reaction to this Dividend King's Q4 revenue miss was overdone. 
Via The Motley Fool
Topics Earnings
News headline image
The Best Dividend Stocks to Buy and Hold Forever ↗
These stocks offer highly attractive dividends and staying power. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is Abbott’s January Pullback a Good Time to Buy? ↗
Via MarketBeat
Which stocks are moving after the closing bell on Friday? ↗
Via Chartmill
Greenland Truces and Intel’s Earnings Bruises: Wall Street’s Identity Crisis ↗
Via Chartmill
Which S&P500 stocks have an unusual volume on Thursday? ↗
Via Chartmill
Abbott Laboratories (NYSE:ABT) Shares Slump on Q4 Revenue Miss and Nutrition Segment Weakness ↗
Via Chartmill
News headline image
Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles
Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
The Software Surge: How 2024’s $25.7 Billion M&A Explosion in Diagnostics Redefined Healthcare
The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
ABT Q4 Deep Dive: Nutrition Weakness and Innovation Shape 2026 Outlook
Healthcare product and device company Abbott Laboratories (NYSE:ABT) missed Wall Street’s revenue expectations in Q4 CY2025 as sales rose 4.4% year on year to $11.46 billion. Its non-GAAP profit of... 
Via StockStory
News headline image
Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting... 
Via MarketMinute
Topics Economy
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Why Abbott Laboratories (ABT) Shares Are Sliding Today
Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.3% in the afternoon session after the company reported fourth-quarter revenue that missed Wall Street's... 
Via StockStory
Top S&P500 movers in Thursday's session ↗
Via Chartmill
News headline image
Abbott (ABT) Q4 2025 Earnings Call Transcript ↗
Abbott (ABT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an... 
Via MarketMinute
Topics Earnings Economy
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
News headline image
NVE (NVEC) Q3 2026 Earnings Call Transcript ↗
NVE (NVEC) Q3 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Supply Chain
News headline image
Abbott Laboratories (NYSE:ABT) Misses Q4 CY2025 Revenue Estimates, Stock Drops
Healthcare product and device company Abbott Laboratories (NYSE:ABT) fell short of the markets revenue expectations in Q4 CY2025 as sales rose 4.4% year on year to $11.46 billion. Its non-GAAP profit... 
Via StockStory
News headline image
Want Decades of Passive Income? 2 Stocks to Buy Right Now. ↗
Their dividend streaks speak volumes. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Abbott Laboratories (ABT) Q4 Earnings Report Preview: What To Look For
Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be announcing earnings results tomorrow before the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.